Mackenzie Financial Corp Reduces Stock Position in Indivior PLC (NASDAQ:INDV)

Mackenzie Financial Corp lowered its holdings in shares of Indivior PLC (NASDAQ:INDV) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 550,640 shares of the company’s stock after selling 11,955 shares during the quarter. Mackenzie Financial Corp owned 0.40% of Indivior worth $8,305,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of INDV. Scopia Capital Management LP purchased a new stake in shares of Indivior in the 3rd quarter worth $191,743,000. Vanguard Group Inc. lifted its holdings in shares of Indivior by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock worth $134,875,000 after buying an additional 90,673 shares during the period. FMR LLC lifted its holdings in shares of Indivior by 53.5% in the 3rd quarter. FMR LLC now owns 5,498,087 shares of the company’s stock worth $119,339,000 after buying an additional 1,915,980 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Indivior in the 2nd quarter worth $83,678,000. Finally, Liontrust Investment Partners LLP purchased a new stake in shares of Indivior in the 3rd quarter worth $43,340,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of NASDAQ INDV opened at $18.52 on Friday. The stock has a market capitalization of $2.55 billion, a P/E ratio of -925.54 and a beta of 0.46. Indivior PLC has a 1-year low of $14.38 and a 1-year high of $26.50. The business has a fifty day moving average price of $20.45 and a 200 day moving average price of $18.40.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15. The firm had revenue of $293.00 million during the quarter, compared to analysts’ expectations of $260.00 million. Indivior had a return on equity of 538.18% and a net margin of 0.18%. As a group, equities research analysts anticipate that Indivior PLC will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum initiated coverage on Indivior in a report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price for the company.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.